Angionetics Overview
- Year Founded
-
2001
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
2
Angionetics General Information
Description
Developer of biotechnology products for cardiac issues. The company is focused on the development and commercialization of novel DNA-based therapeutics designed to promote the heart's innate natural capacity to modulate the formation and growth of cardiac microvascular circulation to enhance blood flow in patients with a variety of ischemia-driven disease conditions and refractory angina and myocardial ischemia due to cardiac microvascular insufficiency (CMI), and other cardiovascular disease conditions.
Contact Information
Website
www.angionetics.com
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 11750 Sorrento Valley Road
- Suite 250
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Angionetics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Angionetics Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Christopher Reinhard | Chief Executive Officer | ||
| Lois Chandler Ph.D | Vice President of Product Development |
Angionetics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|